Edition:
India

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

16.16CNY
8:59am IST
Change (% chg)

¥0.02 (+0.12%)
Prev Close
¥16.14
Open
¥15.92
Day's High
¥16.45
Day's Low
¥15.80
Volume
8,867,539
Avg. Vol
19,612,531
52-wk High
¥32.83
52-wk Low
¥9.80

Select another date:

Mon, Oct 15 2018

Photo

EU places China's Zhejiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

UPDATE 1-EU places China's Zhejiang Huahai under increased supervision

Oct 15 European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

EU places China's Zheijiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, after an inspection revealed lapses in quality management at the drugmaker's factory in China.

EU places China's Zheijiang Huahai under increased supervision

Oct 15 European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, after an inspection revealed lapses in quality management at the drugmaker's factory in China.

Embattled Chinese drug maker to get $43 mln in government support

SHANGHAI, Oct 14 A Chinese city government has given 300 million yuan ($43 million) to drug maker Zhejiang Huahai Pharmaceuticals, the company said, after it was recently faulted by U.S. and European regulators over production issues at one of its plants.

CORRECTED-(OFFICIAL)-UPDATE 3-FDA halts imports from China's Huahai Chuannan plant

SHANGHAI/NEW YORK, Sept 28 The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced at China's Zhejiang Huahai Pharmaceuticals Chuannan factory, after a recall of one of its drugs that contained a probable carcinogen.

Chinese drugmaker Huahai tumbles after FDA shutout

SHANGHAI Shares of China's Zhejiang Huahai Pharmaceuticals Co Ltd tumbled in early trade on Monday, the first day of trading since the U.S. Food and Drug Administration halted imports of drug ingredients or medicines made by the company.

FDA halts imports from China's Huahai after heart drug recall

SHANGHAI/NEW YORK The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced by China's Zhejiang Huahai Pharmaceuticals, after a recall of one of its drugs that contained a probable carcinogen.

Select another date: